Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Immuron Ltd's Canadian Partner, Paladin Labs Inc Receives Marketing Approval For Travelan In Canada


Tuesday, 12 Nov 2013 05:54pm EST 

Immuron Ltd announced that its Canadian partner for Travelan, Paladin Labs Inc., has received from Health Canada a Product License authorizing the sale of Travelan in Canada. Similarly to the Australian listing for Travelan, the authorization granted to Paladin Labs is for tablets comprising 200mg of Immuron’s anti-ETEC hyperimmune bovine colostrum. In Canada, Travelan is classified as a Natural Health Product and will be available to patients over-thecounter, without the requirement to obtain a prescription. The authorization for Travelan in Canada entitles Paladin Labs to claim on the product package that it is Clinically Proven to Help Reduce the Risk of Travellers’ Diarrhea. 

Company Quote

0.0070
0.0010 +16.67%
21 Aug 2014